Panelists discuss how health care providers can develop comprehensive management protocols for talquetamab-related toxicities by consulting with specialists, gathering patient feedback, and creating detailed handouts that empower patients to proactively manage adverse effects before they begin treatment.
Samantha Shenoy, NP, MSN, developed a comprehensive toxicity management protocol based on 5 years of clinical experience with patients on talquetamab, beginning with clinical trial participants. The protocol evolved through consultation with dermatologists, dietitians, colleagues at other institutions, and direct patient feedback about effective management strategies. This collaborative approach resulted in a 3- to 4-page handout covering taste changes, dry mouth, skin changes, nail changes, and weight loss management.
The handout provides practical, actionable recommendations organized by toxicity type, including specific product recommendations for managing each adverse effect category. For skin toxicities, recommendations include using emollients, ammonium lactate cream, and topical steroids for palmar-plantar peeling, along with lukewarm showers and immediate post-shower moisturizing. Nail care strategies involve nail hardeners, vitamin E cuticle oil, protective coverings such as finger cots, and trauma prevention through proper footwear and activity modifications.
The proactive distribution of educational materials before treatment initiation empowers patients to prepare by purchasing recommended products and understanding what to expect during therapy. The protocol emphasizes patient empowerment through preparation, suggesting patients keep materials accessible for ongoing reference rather than attempting to absorb all information at once. This systematic approach to toxicity management represents a scalable model for other institutions implementing bispecific antibody programs.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.